nafamostat has been researched along with Helicobacter Infections in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Helicobacter Infections: Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kajikawa, H | 1 |
| Yoshida, N | 1 |
| Katada, K | 1 |
| Hirayama, F | 1 |
| Handa, O | 1 |
| Kokura, S | 1 |
| Naito, Y | 1 |
| Yoshikawa, T | 1 |
1 other study available for nafamostat and Helicobacter Infections
| Article | Year |
|---|---|
Helicobacter pylori activates gastric epithelial cells to produce interleukin-8 via protease-activated receptor 2.
Topics: Antibodies; Benzamidines; Cell Line, Tumor; Epithelial Cells; Gastric Mucosa; Gene Expression; Guani | 2007 |